Assessment Instrument | Aims | Variables | Screening | Baseline | 3-mo F-U | 6-mo F-U | 9-mo F-U | 12-mo F-U |
---|---|---|---|---|---|---|---|---|
MINI DSM-5 | 1,S | substance use disorder | x | Â | Â | Â | Â | Â |
HIV Rapid Antibody Test | 1,S | HIV status | Â | x | Â | Â | Â | Â |
ASK-PrEP Admission/Follow-up Assessment | 1,S | demographics; individual-level characteristics; social/structural determinants | Â | x | x | x | x | x |
Timeline Follow-Back***** | 1,S | Current substance use | Â | x | x | x | x | x |
NBA* / NBA-Lite** | 1,S, E | needs, barriers and facilitators | Â | Â | Â | Â | Â | Â |
PrEP Care Continuum | 1,S, E | PrEP initiation, adherence, persistence; PrEP advancement | Â | x | x | x | x | x |
HIV-ASES | 1 | components of PrEP self-efficacy | Â | x | x | x | x | x |
DBS*** | 1,S, E | oral daily PrEP adherence and persistence | Â | x | x | x | x | x |
Urine Drug Screen | 1,S | current substance use | Â | x | x | x | x | x |
HIV Ag/Ab and Viral Load Test | 1,S, E | HIV seroconversion | Â | Â | x | x | x | x |
Electronic Health Records | 1,S, E | PrEP care, PrEP prescriptions, PrEP advancement, liver and kidney functions | Â | x | x | x | x | x |
DATCAP**** | 2 | intervention cost | Â | x | x | x | x | x |
NMOS | 2 | resource costs | Â | x | x | x | x | x |
PROPr | 2 | HRQoL, QALYs | Â | x | x | x | x | x |
Locator Form | n/a | Â | Â | x | x | x | x | Â |